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Background: Closed-loop (CL) systems aims to outperform usual treatments 
in blood glucose control and continuous glucose monitors (CGM) are a key 
component in such systems. Meals represents one of the main disturbances in 
blood glucose control, and postprandial period (PP) is a challenging situation 
for both CL system and CGM accuracy. 
Methods: We performed an extensive analysis of sensor’s performance by 
numerical accuracy and precision during PP, as well as its influence in blood 
glucose control under CL therapy. 
Results: During PP the Mean Absolut Relative Difference (MARD) for both 
sensors presented lower accuracy in the hypoglycemic range (19.4 ± 12.8%.) 
than in other ranges (12.2 ± 8.6% in euglycemic range and 9.3 ± 9.3% in 
hyperglycemic range). The overall MARD was 12.1 ± 8.2%. We have also 
observed lower MARD for rates of change between 0 and 2 mg/dl. In CL 
therapy, the 10 trials with the best sensor spent less time in hypoglycemia (PG 
< 70 mg/dl) than the 10 trials with the worst sensors (2 ± 7 min vs 32 ± 38 min, 
respectively).  
Conclusions: In terms of accuracy, our results resemble to previously reported. 
Furthermore, our results showed that sensors with the lowest MARD spent less 
time in hypoglycemic range, indicating that the performance of CL algorithm 
to control PP was related to sensor accuracy. 
  




Achieving recommended glycemic targets is difficult for patients with 
type 1 diabetes (T1D), despite high motivation and substantial time spent for 
controlling in everyday life. Currently, despite increasingly effective treatments 
and glucose monitoring systems, the majority of individuals with T1D still 
cannot achieve recommended glycemic goals. In this context, there is an 
increasing awareness that maybe the best solution for T1D patients could be a 
closed-loop system that can independently restore insulin needs and provide 
good glycemic balance. This system can deliver insulin automatically, by 
continuous subcutaneous insulin infusion (CSII). In addition, a designed 
glycemic control algorithm calculates de amount of insulin to be delivered based 
on continuous glucose measurements obtained by means of a subcutaneous 
glucose sensor connected wireless to a glucose monitor, i.e. continuous glucose 
monitoring (CGM).1 
Accuracy of CGMs’ measurements have been improved over the years, 
and FDA has recently approved the commercialization of a closed-loop (CL) 
device that relies on CGM measures to automatically delivery insulin to T1D 
patients. As CGM measures the glucose in the interstitial fluid, there is a 
physiological delay due to the fact that glucose must be transported from blood 
to interstitium. Besides that, inherent sensor properties and the dynamic profile 
of PG excursions affect sensors’ accuracy.2–4 Therefore, a mismatch in relation 
to the blood glucose measurements is still present. Consequently, these 
differences diminish controller’s performance and glycemic management, but it 
is not an impediment for the usage in CL systems.5 In a previous study,6 the 
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consequences of CGM limitations were analyzed in-silico in CL performance, 
by incorporating real CGM device characteristics into the UVa/Padova 
simulator. This study showed that poorly CGM performance might have a 
relevant impact on closed-loop outcomes. Additionally, in another study, lack 
of CGM accuracy resulted in poor postbreakfast control and patients with most 
hypoglycemic alarms were also those with the highest CGM’s errors.7  
In this study, an evaluation of numerical and clinical accuracy of 
Paradigm Veo® system with the Enlite-2 sensors® (Medtronic MiniMed, 
Northridge, CA), from here on ENL, was performed during postprandial period 
(PP), using data obtained from a previous closed-loop clinical trial.8 In addition 
to this, the individual performance closed-loop trials across the study was also 




Study Procedure, Devices and Population 
 
Twenty T1D subjects underwent an 8-hour standardized mixed meal test 
(60g carbohydrate, CHO) on 4 occasions. On 2 occasions (Open-loop – OL), 
conventional CSII was used and boluses were based on the individual insulin-
to-carbohydrates ratios. On the other two occasions, after a meal-
announcement, an augmented bolus was given, followed by manual adjustments 
of the basal rate every 15 minutes according to a CL controller recommendation. 
CSII was carried out with the Paradigm Veo® insulin pump and CGM 
using ENL. Two CGM were inserted at least 24 hours before the meals tests and 
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were calibrated using the Contour® Next Link (Ascensia Diabetes Care 
Holdings AG, Basel, Switzerland. Formerly Bayer) 30 minutes before a lunch 
meal. Although two sensors were used during the study for safety and regulatory 
reasons, only one was used to feed the CL algorithm. The second sensor was 
used just in case of failure or malfunction of the first sensor. Definition of the 
primary CGM (from here on Main CGM) was performed automatically by the 
system, based on an accuracy analysis prior to the start of the CL operation. 
Malfunction has been defined as Absolut Relative Difference (ARD) greater 
than 30% between CGM and Plasma Glucose (PG) reference at two 
consecutives samples or greater than 40% at one-time point. 
Two venous lines were prepared, one for arterialized venous blood 
sampling and the other for insulin/glucose infusion, if required. PG samples 
were measured every 15 min using YSI 2300 Stat Plus Glucose Analyzer (YSI 
Inc., Yellow Springs, OH, USA). To ensure comparable metabolic conditions 
between studies, subjects received intravenous infusion of regular human 
insulin or glucose to maintain plasma glucose at 90-100 mg/dl, until the 
beginning of studies at 12:00. During an 8-h period, postprandial glucose was 
monitored and OL or CL insulin therapies were applied. Following insulin 
administration, if plasma glucose fall below 70 mg/dl during two consecutive 
readings, a fixed amount of 15 g of oral glucose was administered in order to 
prevent hypoglycemia. Table 1 summarizes the main demographics 
characteristics of the patients included in this study. Figure 1 shows the protocol 
details during the sessions. More information about the trial can be found 
elsewhere.8 
 




CGM data were registered every 5 minutes and PG data were recorded 
every 15 minutes. In order to align CGM and PG data, CGM data were linearly 
interpolated and rounded to 1 sample per minute. Missing data were not 
interpolated.  
In this work, the accuracy and precision of the CGM sensors were 
evaluated by the Mean ARD (MARD) and Precision Absolute Relative 
Difference (PARD).9–13 Due to the specific conditions and duration of the trial, 
we perform the analysis of the short-term MARD (during 8-h) in this work, 
however, the term MARD is used in the text. The performance of the CL trials 
was assessed according to the 10 best and worst accurate sensors, sorted by the 
MARD. Clinical accuracy was analyzed with the Clarke’s Error Grid Analysis 
(EGA),14 International Organization for Standardization (ISO) Criteria (ISO 
15197:2013),15 and Bland-Altman Analysis.16  
Overall average and aggregated MARD and PARD were calculated for 
all sessions and categorized into glucose ranges <70, 70-180, and >180 mg/dl, 
as it was performed in other studies.10,11 The average MARD and PARD results 
were evaluated as averages across all the sessions. MARD and error (error = PG 
– CGM) were also analyzed according to the PG rate of change. 
Relative differences were evaluated as averages across all the sessions 
(n = 74 and n = 148, for PARD and MARD, respectively). The aggregated 
MARD and PARD were calculated as the aggregated mean of overall data. The 
average MARD and PARD in the glucose ranges considered only the sessions 
that presented hypoglycemic or hyperglycemic events. Aggregated MARD and 
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PARD in the glucose ranges considered all MARD and PARD data categorized 
in each glucose range. For the CL sessions, the average and aggregated MARD 
results of the Main CGM were compared with the results of both CGMs (i.e. if 
only 6 of all the sessions presented hypoglycemic events, the MARD results on 
the hypoglycemic range will count with n=12 when both CGMs are considered 
or n=6, if only the Main CGM is considered). 
Different values of average and aggregated MARD and PARD are 
expected due to the number of individual paired data points is not exactly the 
same from subject to subject as well as the amount of time spent in each glucose 
concentration. 
The MARD of the main sensor of CL trials was sorted ascendingly. The 
10 most accurate sensors were chosen as the 10 best CL sensors. The 10 least 
accurate sensors were chosen as the 10 worst CL sensors. This allowed the 
evaluation of the effects of the accuracy of the sensors in the CL trials. 
Times in each glycemic range were calculated for PG and CGM 
measurements for the sessions with 10 best and 10 worst CL sensors. Results 
were analyzed through Mean ± Standard Deviation (SD) and Median 
(Interquartile Range - IQR). The Anderson-Darling Normality test was used to 
determine the normality of the data. For data that does not follow a normal 




The impact of accuracy of CGM was observed during 8-h PP. During the CL 
sessions, a meal bolus was combined with the controller’s insulin infusion, as a 
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feedforward action, to reduce the prandial peak. It is well known that meals are 
the major disturbance that causes large glycemic excursions. In our study, even 
with a meal contending 60 grams of CHO, the majority (77.1%) of the rates of 
change of glycemia were between -1 and 1 mg/dl/min.  
 
Effects of the CGM accuracy in closed-loop performance 
 
Table 2 presents the MARDs of the 10 best and 10 worst main sensors 
of the CL trials. Both average and aggregated MARDs of the 10 best are about 
15.3% lower than average and aggregated MARD of the 10 worst sensors. 
Table 3 presents the time (in minutes) spent in, above and below the 
range for 10 best CL sensors and 10 worst CL sensors, calculated either with 
PG or CGM measurements. Table 4 shows the glucose rescues during the CL 
therapy. In only one of the 10 trials that considered the best sensors occurred 
hypoglycemia and administration of oral glucose (rescue) one time. When the 
10 trials with the worst sensors were considered, in five trials there was 
administration of oral glucose, with a total of 13 rescues. Figure 2 shows the 
mean values of CGM and PG readings for the 10 CL trials with worst MARD. 
Figure 2(a) represents the 5 trials in which no glucose rescues were required and 
Figure 2(b) shows the 5 trials in which glucose rescues were necessary.  
 
MARD and PARD 
Table 5 shows the average and aggregated MARD and PARD for all 
sessions. The overall average and aggregated MARD were equal to 12.0 ± 7.5 
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% (n=148, 74 sessions, 2 sensors per session) and 12.0 ± 11.2 % (n = 4851), 
respectively.  
Average and aggregated MARD in the euglycemic range were equal to 
12.5 ± 8.2 (n=148) and 12.3 ± 11.5 (n=3216), respectively. These values were 
higher than the values obtained in the hyperglycemic range, where better 
accuracy was achieved.  
Figure 3 shows an illustration of the CGMs readings considering the best 
and the worst average PARD values between all sessions. PG reference is also 
shown.  Figure 3(a) shows that the readings of CGM1 and CGM2 almost 
overlap each other, which indicates a good precision. Figure 3(b) shows the 
worst average PARD value obtained between all sensors. This graph illustrates 
a lack of precision between this pair of CGMs. Considering Figure 3(b), at the 
beginning of the session, both CGMs present small variations in relation to the 
PG reference. After approximately one hour of the beginning of the session, 
both sensors diverge from the PG reference: CGM1 is higher than PG reference 
and CGM2 is lower than PG reference. CGM1 is overestimating PG, it could 
lead to excessive insulin delivery and development of hypoglycemia. 
Analogously, CGM2 is underestimating PG, which could lead to hyperglycemia 
due to the lack of insulin. However further conclusions regarding the error must 
take into account the control algorithm embedded in each CL system. 
 
MARD – Main CGM 
 
Table 6 compares the value of the MARD for the CL trials using both 
CGM sensors and using the Main CGM. It is clear that the overall average and 
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aggregated MARD values for the Main CGM are lower than when both CGMs 
are considered. This happens due to the procedure of switching between the two 
CGMs in order to use the best one as the input of the control algorithm.  
 
Accuracy according to PG rate of change 
 
Table 7 shows the MARD, median ARD and the mean error related to 
the PG rate of change. We observed an increase in MARDs as absolute value of 
rate of change increases, especially for negative values of changes. In 
accordance with other publication17, sensor errors tend to be positive (CGM 
readings lower than PG) when the PG rate of change is positive and negative 
(CGM readings higher than PG) when the PG rate of change is negative. 
 
Analysis of Clinical Accuracy 
 
The analysis of clinical accuracy has been performed using Clarke EGA, 
ISO Criteria and Bland-Altman Analysis. Considering both CGM sensors and 
all sessions (n = 2630), the EGA yielded 83.45%, 15.32%, 0.02%, 1.22%, and 
0.00% of paired measurement results in zones A, B, C, D, and E, respectively 
According to the ISO Criteria, 82.05% of the data pairs were considered correct 
and 17.95%, incorrect. Considering the Bland-Altman analysis, the mean of the 
differences between PG and CGM readings is equal to 2.44 ± 23.73 mg/dl, with 
agreement limits of +48.96 mg/dl and -44.07 mg/dl. Numerically, 94.9% of the 
data lied between the agreement limits. 
 




In our study, ENL showed in the PP numerical accuracy closed to that 
previously reported in different glucose ranges in other time periods of the day 
and tends to be lower with higher rates of change in glucose. More importantly, 
our results indicate that the accuracy of the sensor could be strongly related to 
the controller’s performance in CL trials.  
We evaluated the consequences of the CGM accuracy in the 
performance of our CL studies using data from the best and worst accurate 
sensors according to MARD. The performance of these trials was assessed by 
the time spent in each predefined glycemic range and also by the quantity of 
glucose rescues for hypoglycemia that were administered during the sessions. 
Considering PG readings, the median time spent in euglycemic range was 
comparable for the trials with both 10 best and 10 worst sensors (443 vs 420 
minutes). The analysis of the same metric using CGM readings showed greater 
difference (454 vs 328 minutes). However, no statistical difference has been 
observed in the results.  
There was a significant reduction in the time spent in the hypoglycemic 
range, when 10 best and worst sensors were compared, for both PG and CGM 
measures. For both PG and CGM readings, the median time spent in 
hypoglycemic range for the 10 best sensors was 0 minutes. Whereas the median 
time spent in the hypoglycemic range during the trials with the 10 worst sensors 
was 19 and 71 minutes, for PG and CGM readings, respectively. Moreover, 
regarding to the number of rescues in case of hypoglycemia (PG < 70 mg/dl), 
there was only one case of administration of oral glucose when the best sensors 
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were considered, while there were five trials that required administration of oral 
glucose when the worst sensors were used.  
To analyze the type of error that induces hypoglycemic events, the 10 
worst CL sessions according to MARD were divided in two groups: sessions 
with and without glucose rescues. Each one of these groups contains five 
sessions. According to Figure 2(a), the mean values of CGM readings are 
consistently below the mean values of PG readings for the trials that did not 
require glucose rescues. However, in Figure 2(b) the mean values of CGM and 
PG readings the same behavior is not noticed. During different times of the 
sessions the mean CGM readings are higher than the mean PG readings, which 
led to excessive insulin delivery for the five sessions that required glucose 
rescues.  
So far, to the authors knowledge, no other publications reported PARD 
results for ENL, impeding a direct comparison and evaluation of our results. 
Pleus and his colleagues11 presented an evaluation of average and aggregated 
PARD of Dexcom G4® stand-alone CGM system (Dexcom, San Diego, CA) 
for 7 days, including periods of induced glucose excursions. Overall average 
and aggregated PARD presented by them was considerably lower than the 
values our study. In their study, overall PARD equals to 7.3 ± 1.9 (n=10), and 
7.3 ± 8.1 (n=96430), average and aggregated, respectively. Our values are about 
80% higher than the values obtained by Pleus et al.11 
We observed different values of average and aggregated PARD for 
different glucose ranges. Sensor precision is poor in the hypoglycemic range, 
according to our results. Pleus and his colleagues11 showed that the G4 sensor 
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is less precise during the hypoglycemic range. For both sensors, the best PARD 
results were obtained in the hyperglycemic range.  
The average and aggregated MARD obtained in our study are lower than 
the values obtained by Kropff and his colleagues,18 but they used a previous 
version of the sensor than the one we used in our project. In both studies the 
worst performance was obtained in the hypoglycemic range. In another study,19 
two Enlite sensors were inserted in the abdomen and evaluated for 24h in adults 
in a clinical research center. Similarly to our trial, sensors were calibrated at the 
beginning of each visit but with the possibility of being recalibrated posteriorly. 
Overall median ARD was 12.6% when CGM measures were compared with 
venous blood samples, a value almost identical to the MARD obtained by us.  
The effects of rate of change in MARD has also been investigated by 
Pleus and colleagues.20 Their results indicates that faster glucose concentration 
changes result in a more pronounced apparent decrease in accuracy. However, 
in our results, the MARD for glucose values rising between 2 and 3 mg/dl/min 
was smaller than the MARD for glucose values falling between -2 and -1 
mg/dl/min (11.61 vs 16.63 %). 
Finally, the comparison of the accuracy between the Main sensor and 
both sensors showed, as expected, that the values presented for the Main CGM 
were lower than the values for both CGM. It should be pointed out that this 
comparison is far from a realistic situation because in real-life use of CGM 
(including CL systems) only one CGM device will be used.  
In addition to the previously mentioned novelties, our study has also 
some limitations. Our study was designed and performed in a controlled clinical 
research in-patient environment and during the PP using a single meal with a 
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specific composition. This limits extrapolation of results to daily life conditions 




In this work we analyzed the short-term accuracy of the ENL sensor 
during PP considering operation in OL and CL. In summary, the ENL showed 
in the postprandial period accuracy closed to that previously reported in 
previous studies. We also noticed that lower errors are related to lower rates of 
change of glucose.  
Considering the sensors used during CL operation, we noticed the trials 
with the 10 best sensors spent less time in the hypoglycemic range than the trials 
with the 10 worst sensors and required less glucose rescues. For the trials with 
worst sensors that did not require glucose rescues, the mean value of PG was 
consistently higher than the mean value of CGM. 
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